Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
← catalyst calendarNCT04421963 · readout in 230 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
185actual
Sites
107
Countries
Belgium, Bulgaria, Canada +20
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-08-04 | actual | When the study began enrolling |
| Primary completion | 2027-04-06 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-04-06 | estimated | The whole study's end, after follow-up |
| First posted | 2020-06-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Ovarian Cancer
- Breast Cancer
Intervention
- Drug: Olaparib
Primary outcome
what the primary-completion date above is the date OFSafety follow up
measured Baseline up to approximately 10 years
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed